Warren is Professor of Dermatology and Therapeutics and Honorary Consultant
Dermatologist at the University of Manchester in the UK. He graduated from
Liverpool University with a first-class honours degree in pharmacology and
gained his medical degree, with honours, one year later. He was awarded The J
Hill Abram prize – highest mark in medicine – and the Reginald Dora Goodrick
prize – highest mark in surgery.
Professor Warren’s work in dermatology has focussed on pharmacogenetics (forming the basis of his PhD thesis), the genetic susceptibility to psoriasis, and more recently biological therapies and their use in the treatment of psoriasis. For his work on the pharmacogenetics of methotrexate, Professor Warren has received national and international awards from the British Association of Dermatologists (BAD) and the American Academy of Dermatology (AAD).
Professor Warren is widely published in the field of dermatology with more than 200 abstracts, papers, and book contributions, including The Lancet, Nature Genetics, and The Journal of Investigative Dermatology. He is currently the EU Editor-in-Chief for Dermatology and Therapy. He has been an invited plenary speaker at major national and international dermatology meetings and is a member of The International Psoriasis Council. Professor Warren currently chairs the BAD guideline group for methotrexate and is a member of the BAD biologics committee and research subcommittee. In 2012, he was the expert panel member on the National Institute for Health and Clinical Excellence guideline group for psoriasis. He is Co-Lead of one of the two workstreams involved in successful funding from the Medical Research Council stratified medicine grant (Value £7 million) - Psoriasis Stratification to Optimise Relevant Therapies (PSORT). Professor Warren is Director of the Dermatopharmacology Unit, one of the largest clinical trials units in Europe. He co-established a clinic for patients with severe psoriasis and psoriatic arthritis in 2010 with Dr Hector Chinoy, which has received wide acclaim and is used as a national exemplar.
EM-15825 - Date of preparation: August 2019